Biotech RadarJobs updated

COMPANY

Biodesix

biodesix.com ↗ · Mountain

Keywords: diagnostics Nodule Solitary Pulmonary Indeterminate Pulmonary Nodule Non-Small Cell Lung Cancer Non-small Cell Carcinoma Lung Nodules NSCLC

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Timeline

  1. Trial start —: Nodify Lung Testing for Pulmonary Nodules source ↗
  2. Trial start —: A Multicenter, Retrospective, Chart Review Study Evaluating the Impact and Utility of the Blood-Based Proteomic Integrated Classifier and Auto-Antibody Tests in the Real-World source ↗
  3. Trial start —: Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules source ↗
  4. Trial start —: A Registry to Evaluate the Performance of the BDX-XL2 Test source ↗
  5. Trial start —: Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT07858552Nodify Lung Testing for Pulmonary NodulesNot listedNot yet recruiting2026-112030-11 (estimated)
NCT03289780Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC SubjectsNot listedActive, not recruitingApr 4, 20162025-12 (estimated)
NCT04171492Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung NodulesNot listedActive, not recruitingDec 18, 20202025-12 (estimated)
NCT06728319A Multicenter, Retrospective, Chart Review Study Evaluating the Impact and Utility of the Blood-Based Proteomic Integrated Classifier and Auto-Antibody Tests in the Real-WorldNot listedActive, not recruitingSep 19, 2024Jul 31, 2026 (estimated)
NCT03766958A Registry to Evaluate the Performance of the BDX-XL2 TestNot listedCompletedOct 16, 2018May 12, 2022 (actual)
Feedback